Evolus, Inc. (LON:0K16)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 365.37M |
| Revenue (ttm) | 202.87M |
| Net Income (ttm) | -45.25M |
| Shares Out | n/a |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52 |
| Average Volume | 3,893 |
| Open | 14.31 |
| Previous Close | 14.16 |
| Day's Range | 14.31 - 14.58 |
| 52-Week Range | 9.31 - 17.81 |
| Beta | n/a |
| RSI | 65.90 |
| Earnings Date | Aug 4, 2025 |
About Evolus
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California. [Read more]
Financial Performance
In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.
Financial numbers in USD Financial StatementsNews
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline r...
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submit...
Insider Buying: Brady Stewart Acquires 30,000 Shares of Evolus Inc (EOLS)
Insider Buying: Brady Stewart Acquires 30,000 Shares of Evolus Inc (EOLS)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August...
Evolus plunges after Q2 miss, guidance cut; Needham downgrades
Evolus (EOLS) Q2 Revenue Rises 4%
Evolus outlines $700M 2028 revenue target and cost realignment amid market softness
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Evolus, Inc. 2025 Q2 - Results - Earnings Call Presentation
Evolus GAAP EPS of -$0.27 misses by $0.07, revenue of $69.4M misses by $12.64M
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial resu...
A Look Ahead: Evolus's Earnings Forecast
Evolus (NASDAQ: EOLS) will release its quarterly earnings report on Tuesday, 2025-08-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Evolus to report an earni...
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of...
Evolus to Report Second Quarter Financial Results on August 5, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
I maintain my Buy rating on Evolus, confident in management's guidance and optimistic about Q2 earnings exceeding Wall Street expectations. Evolus is demonstrating strong market share gains, successfu...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July o...
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered w...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June o...
Evolysse™ Recognized in 2025 Shape Skin Awards
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been r...
Evolus announces CFO resignation
Evolus Announces Departure of its Chief Financial Officer
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Fin...
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of...